ArticleJournal of child and adolescent psychopharmacology2011
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Article in Journal of child and adolescent psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients.European journal of drug metabolism and pharmacokinetics · 2019Trial
- Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients.BMC psychiatry · 2024Article
- Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics.Frontiers in psychiatry · 2024Article
- Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode.Frontiers in psychiatry · 2023Article
- Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder.British journal of clinical pharmacology · 2021Observational
- A Machine Learning Model to Predict Risperidone Active Moiety Concentration Based on Initial Therapeutic Drug Monitoring.Frontiers in psychiatry · 2021Article
- Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Article
- How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?Frontiers in genetics · 2020Review
- CYP2D6 genotype and adverse events to risperidone in children and adolescents.Pediatric research · 2019Article
- A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents.Child and adolescent psychiatry and mental health · 2018Review
- Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.Journal of personalized medicine · 2017Article
- Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.Journal of clinical laboratory analysis · 2016Article
- Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings.European journal of clinical pharmacology · 2016Observational
- Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.European child & adolescent psychiatry · 2013Review
- Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Paediatric drugs · 2013Review
- Iron deficiency in pediatric patients in long-term risperidone treatment.Journal of child and adolescent psychopharmacology · 2013Article
- Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.Therapeutic drug monitoring · 2012Article
- Correlates of weight gain during long-term risperidone treatment in children and adolescents.Child and adolescent psychiatry and mental health · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionLittle is known about risperidone metabolism in a clinical sample, where polypharmacy is common. Such knowledge is important since several of its side effects are dose dependent.
methodsMedically healthy patients aged 7 to 17 years old treated with risperidone for at least 6 months were enrolled. Trough serum risperidone and 9-hydroxyrisperidone concentrations were measured.
resultsOne hundred seven participants (92% males) were recruited, representing a heterogenous clinical group with attention-deficit/hyperactivity disorder, disruptive behavior disorders, pervasive developmental disorders, anxiety disorders, mood disorders, tic disorders, or psychotic disorders. Risperidone had been used at a mean dose of 0.03 mg/kg, for a mean 2.5 years, predominantly to treat irritability and aggression. Cytochrome CYP2D6 inhibitors were divided into prominent (fluoxetine, bupropion, and lamotrigine), intermediate (sertraline), and weak inhibition groups (citalopram or escitalopram). The concentrations of risperidone and its metabolite were strongly associated with the dose of risperidone and time since the last dose and, to a lesser extent, with male sex. In addition, risperidone concentration increased with pubertal stage (p < 0.05), while body mass index z-score (p = 0.001) predicted a higher 9-hydroxyrisperidone concentration. The use of CYP2D6 inhibitors was much more strongly associated with risperidone concentration (p < 0.0001) than with its metabolite's (p = 0.06).
conclusionsIn chronically treated youths, the metabolism of risperidone depends on the stage of sexual development, whereas that of 9-hydroxyrisperidone varies with body fat. Moreover, CYP2D6 inhibitors more strongly affect risperidone metabolism than that of its metabolite. The clinical implications of these findings, in relation to efficacy and tolerability, deserve further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.